I-Mab (NASDAQ:IMAB – Get Free Report)’s stock price was down 3.8% during trading on Friday . The company traded as low as $1.23 and last traded at $1.26. Approximately 150,879 shares changed hands during mid-day trading, a decline of 56% from the average daily volume of 345,044 shares. The stock had previously closed at $1.31.
Analyst Upgrades and Downgrades
Separately, Needham & Company LLC restated a “buy” rating and issued a $6.00 target price on shares of I-Mab in a research report on Friday, April 12th.
View Our Latest Report on I-Mab
I-Mab Stock Down 3.8 %
Hedge Funds Weigh In On I-Mab
A hedge fund recently bought a new stake in I-Mab stock. abrdn plc purchased a new stake in I-Mab (NASDAQ:IMAB – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 162,580 shares of the company’s stock, valued at approximately $309,000. abrdn plc owned approximately 0.20% of I-Mab at the end of the most recent reporting period. Institutional investors own 38.38% of the company’s stock.
About I-Mab
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial.
Recommended Stories
- Five stocks we like better than I-Mab
- Which Wall Street Analysts are the Most Accurate?
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- What is a Dividend King?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What Are Dividend Champions? How to Invest in the Champions
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.